The fact that SOX2–IGF2/IGF1R signaling axis confers aggressiveness in bladder cancer suggests that IGF2/IGF1R may serve as therapeutic targets in treating bladder cancer. The gene discussed is IGF2; the disease is urinary bladder carcinoma.